Quick answers
- What is Selegiline used for?
- The FDA-approved label (Emsam, Viatris Specialty LLC, May 15, 2020) says: “EMSAM (selegiline transdermal system) is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of adults with major depressive disorder (MDD) […]. EMSAM ® (selegiline transdermal system) is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of major depressive disorder (MDD).” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Selegiline have a boxed warning?
- Yes. The FDA label for Emsam has a boxed warning (“WARNING: SUICIDAL THOUGHTS AND BEHAVIORS”), the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Selegiline?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Selegiline been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Selegiline?
- 13 companies list prescription products of Selegiline in the FDA NDC Directory, including Viatris Specialty LLC, Apotex Corp. and Bryant Ranch Prepack.
What Selegiline is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
EMSAM (selegiline transdermal system) is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of adults with major depressive disorder (MDD) […]. EMSAM ® (selegiline transdermal system) is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of major depressive disorder (MDD).
— FDA label: Emsam, Viatris Specialty LLC, effective May 15, 2020. Read the full label on DailyMed →
The FDA has 13 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Its heading: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
. Read it on the full label →
1 of 13 FDA labels for this medicine have a boxed warning.
Forms and how it is given
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| selegiline 12 mg/24 h patch | Brand: Emsam | $75.35 per patch |
| selegiline 6 mg/24 h patch | Brand: Emsam | $75.04 per patch |
| selegiline 9 mg/24 h patch | Brand: Emsam | $75.18 per patch |
| selegiline hydrochloride 5 mg capsule | Generic | $0.7541 per capsule |
| selegiline hydrochloride 5 mg tablet | Generic | $0.8074 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Viatris Specialty LLC3 products
- Apotex Corp.2 products
- Bryant Ranch Prepack2 products
- A-S Medication Solutions1 product
- A2A Integrated Pharmaceuticals1 product
- Marlex Pharmaceuticals, Inc.1 product
- Golden State Medical Supply, Inc.1 product
- Rising Pharma Holdings, Inc.1 product
- Bausch Health US, LLC1 product
- i3 Pharmaceuticals, LLC1 product
- Chartwell RX, LLC1 product
- Novitium Pharma LLC1 product
- Proficient Rx LP1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA021336 EMSAM | Somerset | February 27, 2006 | 7, latest July 14, 2017 2017: Labeling · 2015: Manufacturing (CMC) · 2015: Labeling |
| NDA021479 ZELAPAR | Bausch | June 14, 2006 | 6, latest June 16, 2021 2021: Labeling · 2019: Labeling · 2015: Manufacturing (CMC) |
Generic approvals (6)
- ANDA074565Chartwell Molecules · August 2, 1996
- ANDA074672Pharmazone · April 1, 1997
- ANDA074871Apotex · June 6, 1997
- ANDA075352Novitium Pharma · November 30, 1998
- ANDA075321Apotex · December 4, 1998
- ANDA206803Rising · April 2, 2019
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Emsam, Viatris Specialty LLC, effective May 15, 2020; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →